A year-long trial involving methodical exposure to small amounts of peanut protein shows promise in  alleviating the most serious peanut allergies.

The results, announced Sunday at a conference of the American College of Allergy, Asthma & Immunology in Seattle, may lead to the first oral medication that could eliminate severe peanut allergies in children.

After six months of treatment followed by six months of maintenance therapy, two-thirds of the 372 children who received the treatment were able to ingest 600 milligrams or more of peanut protein — the equivalent of two peanuts — without developing allergic symptoms.

Check out this article in the New York Times.